Table of Contents
Table of Contents
List of Exhibits
Chapter One: Executive Summary
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting the Rx-to-OTC Switches Market
Leading Competitors
Chapter Two
Introduction
Overview of the Over-the-Counter Market
Development of the Rx-to-OTC Drug Market
Rx-to-OTC Industry Structure
Economic Indicators
The FDA and Rx-to-OTC Switches
Chapter Three
Allergy, Cough, Cold, and Sinus Products
Overview
Antihistamines
Decongestants
Cough Preparations
Mast Cell Stabilizers
Ophthalmic Preparations
Description of Conditions
Allergic Rhinitis
Common Cold
Sinusitis
Hives
Ocular Allergies
Prevalence and Incidence
Product Analysis
Current OTC Switched Products
Antihistamines
Decongestants
Cough Preparations
Mast Cell Stabilizers
Ophthalmic Preparations
Prescription Products with Anticipated OTC Approvals
Allegra
Clarinex
Flonase
Nasacort AQ
Nasonex
Market Analysis
Market Size and Forecast
Competitive Analysis
Chapter Four
Analgesics and Other Pain Relievers
Overview
Analgesics
Nonsteroidal Anti-inflammatory Drugs
Topical Pain Relievers and Other Similar Products
Description of Conditions
Pain
Inflammation
Prevalence and Incidence
Product Analysis
Current OTC Switched Products
Antipruritic
Internal analgesic/antipyretic
Oral anesthetic
Prescription Products with Anticipated OTC Approvals
Nonsteroidal anti-inflammatory drugs
Migraine treatments
Market Analysis
Market Size and Forecast
Competitive Analysis
Chapter Five
Anti-infectives
Overview
Antibiotics
Antifungals
Antivirals
Antiparasitics
Description of Conditions
Vaginal Infections
Athlete’s Foot
Jock Itch
Ringworm
Dandruff
Scabies and Pediculosis
Pinworm
Fungal Nail Infections
Prevalence and Incidence
Product Analysis
Current OTC Switched Products
Prescription Products with Anticipated OTC Approvals
Antivirals
Antibiotics
Antifungals
Market Analysis
Market Size and Forecast
Competitive Analysis
Chapter Six
Gastrointestinal Drugs
Overview
Description of Conditions
Nausea
Diarrhea
Constipation
Heartburn
Acid reflux
Prevalence and Incidence
Product Analysis
Current OTC Switched Products
Histamine H2 Inhibitors
Proton Pump Inhibitors
Antidiarrheals
Laxatives
Antiemetics
Prescription Products with Anticipated OTC Approvals
Proton Pump Inhibitors
Mucosal Protectants
Antiemetics
Market and Competitive Analysis
Market Size and Forecast
Competitive Analysis
Chapter Seven
Smoking Cessation
Overview
Description of Conditions
Prevalence and Incidence
Lung Cancer and Tobacco Use
Product Analysis
Current OTC Switched Products
Prescription Products with Anticipated OTC Approvals
Market Analysis
Market Size and Forecast
Competitive Analysis
Chapter Eight
Other Drug Classifications
Overview
Contraceptives
Dental Rinses and Fluorides
Hair Growth Products
Rectal Ointments
Sleep Aids
Weight Management
Description of Conditions
Pregnancy
Dental carries
Hereditary Hair Loss
Hemorrhoids
Sleeplessness
Obesity
Conditions with Possible Future OTC Treatments
Elevated Cholesterol
Osteoporosis
Acne Vulgaris
Menopause and Hormone Replacement
Prevalence and Incidence
Product Analysis
Current OTC Switched Products
Contraceptives
Dental rinses and fluoride
Hair growth
Rectal ointments
Sleep aids
Weight Management
Prescription Products with Anticipated OTC Approvals
Antilipidemics/ Osteoporosis/ Hormone Replacement
Hair Loss Treatment
Acne Treatments
Overactive Bladder
Sexual Dysfunction
Market Analysis
Market Size and Forecast
New Product Segments; Post 2013
Osteoporosis and Hormone Replacement
Overactive Bladder
Sexual Dysfunction
Competitive Analysis
Chapter Nine
Total Market Summary
Overview
Total market Size and Forecast
Competitive Analysis
Market Analysis
Chapter Ten: Issues and Trends Affecting the Rx-to-OTC Market
Introduction
Regulatory Authorities
A Third Class of Drug
Insurance Issues and Reimbursement for OTC Drugs
Health Insurance Trends in the United States
Healthcare Flexible Spending Accounts and OTC Medicines
Impact on the Consumer
Online Resources for Health Information
OTC Availability
Health Expenditures
Pharmacists Role
Impact on the Prescription Drug Manufacturer
Strategies for Continued Product Growth
Dual Status Switching
Generic Competition
Direct-to-Consumer Advertising
Patent Expiration
Labeling Changes
International Trends in Rx-to-OTC Switches
Prescription vs Over-the-Counter Industry
World Health, Demographics and Life Expectancy
Life Expectancy
Declining Growth of the World Population
Birth Rates
Chapter Eleven: Company Profiles
Introduction
GlaxoSmithKline
Johnson & Johnson
Novartis
Procter & Gamble
Schering-Plough
Wyeth
APPENDIX: Company Directory
Table of Contents
List of Exhibits
Chapter One
Executive Summary
Table 1-1 – The U.S. Market for Rx-to-OTC Switches 2004-2013
Compound Annual Growth Rate
Figure 1-1 – The U.S. Market for Rx-to-OTC Switches, 2004-2013
Chapter Two
Introduction
Table 2-1 – OTC Retail Sales, 1976-2007
Table 2-2 – Rx-to-OTC Switches Approved by the FDA 1976-2007
Figure 2-1 – Number of New Rx-to-OTC Switches per Year 1976-2007
Table 2-3 – Statistics for Selected Rx-to-OTC Switches (United States)
Table 2-4 – Estimated OTC Sales by Product Type and Percent of Sales Attributed to Rx-to-OTC Switched Ingredients
Table 2-5 – U.S. Population by Sex and Selected Age Group, 1997-2017
Figure 2-2 – U.S. Population by Sex, 1997-2017
Figure 2-3 – U.S. Population by Selected Age Group, 1997-2017
Table 2-6 – Healthcare Industry Inflation Rates Healthcare Industry Consumer Price Index Comparisons Based on 2008 Data
Figure 2-4 – Healthcare Industry Inflation Rates Healthcare Industry Consumer Price Index Comparisons Based on 2008 Data
Chapter Three
Allergy, Cough, Cold, and Sinus Products
Table 3-1 – United States Incidence of Allergy, Cough, Cold, Sinus Conditions 2008
Figure 3-1 – United States Incidence of Allergy, Cough, Cold, Sinus Conditions, Superimposed on Total Population, 2008
Table 3-2 – Allergy, Cough, Cold, Sinus Product Ingredients Transferred from Rx-to-OTC Status by Trade Name, Distributor, and Date of OTC Approval
Table 3-3 – Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
Table 3-4 – The U.S. Market for Rx-to-OTC Switches Allergy, Cough, Cold, and Sinus Product Revenues 2004-2008
Compound Annual Growth Rate
Table 3-5 – The Forecasted U.S. Market for Rx-to-OTC Switches Allergy, Cough, Cold, and Sinus Product Revenues 2009-2013
Compound Annual Growth Rate
Figure 3-2 – The U.S. Market for Rx-to-OTC Switches Allergy, Cough, Cold, and Sinus Product Revenues 2004-2013
Figure 3-3 – The U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold, and Sinus Products, by Percent and Product Type, 2008
Table 3-6 – Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold, and Sinus Products, 2008
Figure 3-4 – Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold, and Sinus Products, 2008
Chapter Four
Analgesics and Other Pain Relievers
Table 4-1 – United States Incidence of Conditions with Pain and Inflammatory Symptoms 2008
Figure 4-1 – United States Incidence of Conditions with Pain and Inflammatory Symptoms Superimposed on Total Population, 2008
Table 4-2 – Analgesics, NSAIDs and Other Ingredients Transferred from Rx-to-OTC Status by Trade Name, Distributor, and Date of OTC Approval
Table 4-3 – Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
Table 4-4 – The U.S. Market for Rx-to-OTC Switches Analgesic Product Revenues 2004-2008
Compound Annual Growth Rate
Table 4-5 – The Forecasted U.S. Market for Rx-to-OTC Switches Analgesic Product Revenues 2009-2013
Compound Annual Growth Rate
Figure 4-2 – The U.S. Market for Rx-to-OTC Switches Analgesic Product Revenues 2004-2013
Figure 4-3 – The U.S. Market for Rx-to-OTC Switches: Analgesic Product Type, 2008
Table 4-6 – Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Analgesics 2008
Figure 4-4 – Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Analgesics 2008
Chapter Five
Anti-infectives
Table 5-1 – United States Yearly Incidence of Infections, 2008
Figure 5-1 – United States Yearly Incidence of Infections Superimposed on Total Population, 2008
Table 5-2 – Anti-infectives Ingredients Transferred from Rx-to-OTC Status by Trade Name, Distributor, and Date of OTC Approval
Table 5-3 – Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
Table 5-4 – The U.S. Market for Rx-to-OTC Switches Anti-infective Product Revenues 2004-2008
Compound Annual Growth Rate
Table 5-5 – The Forecasted U.S. Market for Rx-to-OTC Switches Anti-infective Product Revenues 2009-2013
Compound Annual Growth Rate
Figure 5-2 – The U.S. Market for Rx-to-OTC Switches Anti-infective Product Revenues 2004-2013
Figure 5-3 – The U.S. Market for Rx-to-OTC Switches: Anti-infective Product Type, 2008
Table 5-6 – Leading Suppliers’ Shares of The U.S. Market for Rx-to-OTC Switched Anti-infectives 2008
Figure 5-4 – Leading Suppliers’ Shares of The U.S. Market for Rx-to-OTC Switched Anti-infectives 2008
Chapter Six
Gastrointestinal Drugs
Table 6-1 – United States Incidence of Gastrointestinal Conditions 2008
Table 6-2 – Gastrointestinal Drug Ingredients Transferred from Rx-to-OTC Status by Trade Name, Distributor, and Date of OTC Approval
Table 6-3 – Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
Table 6-4 – The U.S. Market for Rx-to-OTC Switches Gastrointestinal Drug Revenues 2004-2008
Compound Annual Growth Rate
Table 6-5 – The Forecasted U.S. Market for Rx-to-OTC Switches Gastrointestinal Drug Revenues 2009-2013
Compound Annual Growth Rate
Figure 6-2 – The U.S. Market for Rx-to-OTC Switches Gastrointestinal Drug Revenues 2004-2013
Figure 6-3 – The U.S. Market for Rx-to-OTC Switches: Gastrointestinal Drug by Product Type, 2008
Table 6-6 – Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Gastrointestinal Drugs 2008
Figure 6-4 – Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Gastrointestinal Drugs 2008
Chapter Seven
Smoking Cessation
Table 7-1 – United States Cigarette Usage in Percent by Age Group, 2006
Figure 7-1 – New Lung Cancer Cases and Deaths for 2008 by Gender, United States
Table 7-2 – New Cases of Lung and Bronchus Cancer by State; Deaths from Lung and Bronchus Cancer by State, 2008 Estimates
Table 7-3 – Smoking Cessation Product Ingredients Transferred from Rx-to-OTC Status by Trade Name, Distributor, and Date of OTC Approval
Table 7-4 – Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
Table 7-5 – The U.S. Market for Rx-to-OTC Switches Smoking Cessation Product Revenues 2004-2008
Compound Annual Growth Rate
Table 7-5 – The Forecasted U.S. Market for Rx-to-OTC Switches Smoking Cessation Product Revenues 2009-2013
Compound Annual Growth Rate
Figure 7-2 – The U.S. Market for Rx-to-OTC Switches Smoking Cessation Product Revenues 2004-2013
Figure 7-3 – The U.S. Market for Rx-to-OTC Switches: Smoking Cessation Product Type, 2008
Table 7-8 – Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Smoking Cessation Drugs 2008
Figure 7-5 – Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Smoking Cessation Drugs 2008
Chapter Eight
Other Drug Classifications
Table 8-1 – United States Incidence of Miscellaneous Conditions for Which There Are Potential Rx-to-OTC Switches 2008
Table 8-2 – Estimated U.S. Contraceptive Use by Method, Five Year Average 2007/2008
Table 8-3 – Miscellaneous Drug Ingredients Transferred from Rx-to-OTC Status by Trade Name, Distributor, and Date of OTC Approval
Table 8-3 – Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
Table 8-4 – The U.S. Market for Rx-to-OTC Switches Other Drug Classification Product Revenues 2004-2008
Compound Annual Growth Rate
Table 8-5 – The Forecasted U.S. Market for Rx-to-OTC Switches Other Drug Classification Product Revenues 2009-2013
Compound Annual Growth Rate
Figure 8-2 – The U.S. Market for Rx-to-OTC Switches Other Drug Classification Product Revenues 2004-2013
Table 8-6 – The U.S. Market for Rx-to-OTC Switches Other Drug Classifications Revenues by Product Type 2004-2013
Compound Annual Growth Rate
Figure 8-3 – The U.S. Market for Rx-to-OTC Switches Other Drug Classifications Revenues by Product Type 2004-2013
Figure 8-4 – The U.S. Market for Rx-to-OTC Switches Other Drug Classifications Distribution of Revenues by Product Type 2008
Table 8-7 – Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Other Drug Classifications 2008
Figure 8-5 – Leading Suppliers’ Shares of the U.S. Market for Rx-o-OTC Switches Other Drug Classifications 2008
Chapter Nine
Total Market Summary
Table 9-1 – The U.S. Market for Rx-to-OTC Switches 2004-2013
Compound Annual Growth Rate
Figure 9-1 – The U.S. Market for Rx-to-OTC Switches, 2004-2013
Markets by Segments
Figure 9-2 – The U.S. Market for Rx-to-OTC Switches by Product Category, 2004-2013
Figure 9-3 – The U.S. Market for Rx-to-OTC Switches, Distribution of Revenues by Product Category 2008
Table 9-4 – Leading Suppliers Significant Segments of Participation within the U.S. Market for Rx-to-OTC Switches, 2008
Figure 9-4 – Leading Suppliers Market Share in the U.S. Market for Rx-to-OTC Switches, 2008
Chapter Ten : Issues and Trends Affecting the Rx-to-OTC Market
Table 10-1: Health Insurance Trends in the United States 2003-2006
Table 10-2: National Healthcare Expenditures in the United States 1960-2010
Figure 10-1: Healthcare Spending as a Percent of GDP in the United States
Figure 10-2: Internet Users per 100 Inhabitants, 1994-2006
Table 10-3:Total Healthcare Expenditures as a Percent of GDP by Country 2004 and 2006
Figure 10-3: Total Healthcare Expenditures as a Percent of GDP by Country 2004 and 2006
Table 10-4: Average Annual Expenditures per Consumer Unit for Healthcare 2004-2006
Figure 10-4: Typical Pharmacist-Consumer OTC Drug Counseling Session
Table 10-5: U.S. Patent Expirations for Select Prescription Pharmaceuticals
Table 10-6: Legal Classification Status of Selected Ingredients Worldwide
Table 10-7: Total Pharmaceutical Markets, Prescription vs. Non-Prescription by Region, 2007
Figure 10-5: Total Pharmaceutical Markets, Prescription vs. Non-Prescription by Region, 2007
Table 10-8: Average Life Expectancy in Years by Country 1980 and 2008
Figure 10-6: Average Life Expectancy in Years by Country 1980 and 2008
Table 10-9: World Population 1980 to 2050
Figure 10-7: World Population 1980 to 2050
Table 10-10: Crude Birth Rate per 1,000 Persons 2000, 2005 and Projected 2010
Figure 10-8: Crude Birth Rate per 1,000 Persons 2000, 2005 and Projected 2010
